Protective effect of GTS-21, a novel nicotinic receptor agonist, on delayed neuronal death induced by ischemia in gerbils

Japanese Journal of Pharmacology

Volumn 76, Issue 1, 1998, Pages 23-29

  Nanri, Masato ^a,b   Yamamoto, Jyunji ^a   Miyake, Hidekazu ^a   Watanabe, Hiroshi ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

GTS 21; Ischemia; Mongolian gerbil; Nicotinic agonist; THA

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; NEUROPROTECTIVE AGENT; NICOTINE; NICOTINIC AGENT; PENTOBARBITAL; TACRINE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; GERBIL; HIPPOCAMPUS; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; ISCHEMIA; LATENT PERIOD; LEARNING; MALE; MEMORY CONSOLIDATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PASSIVE AVOIDANCE;

EID: 0031938318     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.76.23     Document Type: Article

References (23)

1. Petito CK, Feldmann E, Pulsinelli WA and Plum F: Delayed hippocampal damage in humans following cardiorespiratory arrest. Neurology 37, 1281-1286 (1987)
2. Wallin A, Alafuzoff I, Carlsson A, Eckernas SA, Gottfries CG, Karlsson I, Svennerholm L and Winblad B: Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 79, 397-406 (1989)
3. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RWR and Symon L: Cerebral blood flow in dementia. Arch Neurol 32, 632-637 (1975)
4. Wieloch T: Neurochemical correlates to selective neuronal vulnerability. Prog Brain Res 63, 69-85 (1985)
5. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernas SA, Nordberg A, Oreland L, Svennerholm L, Wiberg A and Winblad B: Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4, 261-271 (1983)
6. Nanri M, Kasahara N, Yamamoto J, Miyake H and Watanabe H: GTS-21, a nicotinic agonist, protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn J Pharmacol 74, 285-289 (1997)
7. Arendash GW, Sengstock GJ, Sanberg PR and Kem WR: Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674, 252-259 (1995)
8. Bjugstad KB, Mahnir VM, Kem WR, Socci DJ and Arendash GW: Long-term treatment with GTS-21 or nicotine enhances water maze performance in aged rats without affecting the density of nicotinic receptor subtypes in neocortex. Drug Dev Res 39, 19-28 (1996)
9. Hunter BE, de Fiebre CM, Papke RL, Kem WR and Meyer EM: A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci Lett 168, 130-134 (1994)
10. Meyer EM, de Fiebre CM, Hunter BE, Simpkins CE, Frauworth N and de Fiebre NEC: Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev Res 31, 127-134 (1994)
11. Woodruff-Pak DS, Li Y-T and Kem WR: A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res 645, 309-317 (1994)
12. Akaike A, Tamura Y, Yokota T, Shimohama S and Kimura J: Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 644, 181-187 (1994)
13. Kaneko S, Maeda T, Kaneko S, Akaike A, Shimohama S and Kimura J: Protective effects of α7 neuronal nicotinic receptor agonist on glutamate-induced neurotoxicity in cultured cortical neurons. Jpn J Pharmacol 71, Suppl I, 171P (1996)
14. Kirino T: Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 239, 57-69 (1982)
15. Karasawa Y, Araki H and Otomo S: Effects of ketanserin and mianserin on delayed neuronal death induced by cerebral ischemia in Mongolian gerbils. Psychopharmacology (Berl) 109, 264-270 (1992)
16. Zoltewicz JA, Prokai-Tatrai K, Bloom LB and Kem WR: Long range transmission of polar effects in cholinergic 3-arylidene anabaseines. Conformations calculated by molecular modeling. Heterocycles 35, 171-179 (1993)
17. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A and Murphy DL: Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology (Berl) 95, 171-175 (1988)
18. Sahakian B, Jones G, Levy R, Gray J and Warburton D: The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154, 797-800 (1989)
19. Perry EK, Perry RH, Blessed G and Tomlinson BE: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1, 189 (1977)
20. Brioni JD, O'neill AB, Kim DJB, Buckley MJ, Decker MW and Arneric SP: Anxiolytic-like effects of the novel cholinergic channel activator ABT-418. J Pharmacol Exp Ther 271, 353-361 (1994)
21. Damaj MI, Creasy KR, Welch SP, Rosecrans JA, Aceto MD and Martin BR: Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology (Berl) 120, 483-490 (1995)
22. Kuroiwa T, Bonnekoh P and Hossmann K-A: Prevention of postischemic hyperthermia prevents ischemic injury of CA1 neurons in gerbils. J Cereb Blood Flow Metab 10, 550-556 (1990)
23. 125I-α-bungarotoxin receptor subtypes. Mol Pharmacol 47, 164-171 (1995)